[BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].

Abstract

2, 6-Dihydroxy-3-cyano pyridine (CNDP) was found from the study of inhibitory effects of pyrimidine and pyridine derivatives on 5-FU degradation catalyzed by dihydrouracil dehydrogenase. CNDP, a new inhibitor on 5-FU degradation was 300 times more effective than uracil. Co-administration of an equi-molar CNDP with some fluorinated pyrimidine preparations potentiated their antitumor activity. Tegafur (FT-207) and EM-FU in combination with CNDP were found most effective. This potentiation was exhibited not only to 5-FU derivatives but also to FdUrd and its derivatives. BOF-A1 and BOF-A2, new compounds combined with CNDP were markedly active against mouse sarcoma 180 and rat Yoshida sarcoma.

• Authors: S Fujii
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 14 Issue 7 Pg. 2244-50 (Jul 1987) ISSN: 0385-0684 [Print] Japan
• PMID: 2955745 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Pyridines
• Pyrimidines
• Floxuridine
• BOF A1
• Tegafur
• 2,6-dihydroxy-3-cyanopyridine
• Uracil
• Emitefur
• pyrimidine
• pyridine
• Fluorouracil

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Floxuridine (administration & dosage, analogs & derivatives, therapeutic use)
• Fluorouracil (administration & dosage, analogs & derivatives, metabolism, therapeutic use)
• Liver (metabolism)
• Mice
• Pyridines (administration & dosage, metabolism)
• Pyrimidines (metabolism)
• Rats
• Sarcoma 180 (drug therapy)
• Sarcoma, Experimental (drug therapy, metabolism)
• Sarcoma, Yoshida (drug therapy)
• Tegafur (administration & dosage)
• Uracil (administration & dosage)